A combination strategy targeting enhancer plasticity exerts synergistic lethality against BETi-resistant leukemia cells

Lei Guo; Jia Li; Hongxiang Zeng; Anna G. Guzman; Tingting Li; Minjung Lee; Yubin Zhou; Margaret A. Goodell; Clifford Stephan; Peter J. A. Davies; Mark A Dawson; Deqiang Sun; Yun Huang

doi:10.1038/s41467-020-14604-6

Nature Communications (Feb 2020)

A combination strategy targeting enhancer plasticity exerts synergistic lethality against BETi-resistant leukemia cells

Lei Guo,
Jia Li,
Hongxiang Zeng,
Anna G. Guzman,
Tingting Li,
Minjung Lee,
Yubin Zhou,
Margaret A. Goodell,
Clifford Stephan,
Peter J. A. Davies,
Mark A Dawson,
Deqiang Sun,
Yun Huang

Affiliations

Lei Guo: Center for Epigenetics & Disease Prevention, Institute of Biosciences and Technology, Texas A&M University
Jia Li: Center for Epigenetics & Disease Prevention, Institute of Biosciences and Technology, Texas A&M University
Hongxiang Zeng: Center for Epigenetics & Disease Prevention, Institute of Biosciences and Technology, Texas A&M University
Anna G. Guzman: Stem Cells and Regenerative Medicine Center, Baylor College of Medicine
Tingting Li: Center for Epigenetics & Disease Prevention, Institute of Biosciences and Technology, Texas A&M University
Minjung Lee: Center for Epigenetics & Disease Prevention, Institute of Biosciences and Technology, Texas A&M University
Yubin Zhou: Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University
Margaret A. Goodell: Stem Cells and Regenerative Medicine Center, Baylor College of Medicine
Clifford Stephan: Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University
Peter J. A. Davies: Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University
Mark A Dawson: Peter MacCallum Cancer Centre
Deqiang Sun: Center for Epigenetics & Disease Prevention, Institute of Biosciences and Technology, Texas A&M University
Yun Huang: Center for Epigenetics & Disease Prevention, Institute of Biosciences and Technology, Texas A&M University

DOI: https://doi.org/10.1038/s41467-020-14604-6
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 16

Abstract

Read online

Epigenetic changes can drive drug resistance in cancer. Here, the authors show that in BET inhibitor resistant leukaemia cells, genome-wide enhancer remodelling drives therapeutic resistance and targeting enhancer plasticity may overcome this resistance.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal